Personalized mRNA vaccine cuts melanoma recurrence risk by 42% in trial
A recent study of a personalized mRNA cancer vaccine showed a 42% reduction in disease recurrence for patients with melanoma compared with the standard of care.
The vaccine is tailored to each patient’s tumor profile, aiming to stimulate the immune system to target cancer cells more effectively. The trial results suggest the approach could improve outcomes for a disease that often returns after initial treatment.
The finding was highlighted in a Pharmalot newsletter column, underscoring growing interest in mRNA‑based therapies for oncology and their potential impact on future treatment strategies.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Pharmalittle: We’re reading about a cancer vaccine, an experimental pancreatic cancer drug, and more”
read at STAT ↗
comments(0)
5-min edit window · permanent after that